Cell therapy for heart attack with shock
Part of Heart & circulation clinical trials.
This trial tests a new type of cell therapy (FAP iCDC) for people who have had a severe heart attack that caused their heart to pump too weakly (cardiogenic shock). The goal is to see if this treatment can help the heart recover better after the artery has been opened.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 79 years old.
- You had a severe heart attack (STEMI) that caused your heart to pump weakly (cardiogenic shock).
- You already had a procedure to open the blocked artery in your heart (like a stent or bypass).
- Your blood pressure stayed very low or you needed medicine to keep it up, and you had signs of poor blood flow (like confusion, cold skin, low urine output, or high lactate).
- You do not have a tear in your heart wall, a history of cardiac arrest, active cancer, uncontrolled infection, or an autoimmune disease needing immune-suppressing drugs.
- You are not pregnant, and you can understand and agree to the trial risks and treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan for people having a severe heart attack that causes cardiogenic shock, where the heart can't pump enough blood. The study uses a special heart pump to support patients during an emergency procedure to open blocked arteries.
This trial tests a new blood-filtering device called Efferon CT for people with cardiogenic shock after a heart attack. The device aims to help your body recover by cleaning harmful substances from your blood, and you might join if you are diagnosed early and don't have other serious health issues.
This early-phase study tests a new type of immune cell therapy (CAR-DC) for people with advanced heart failure due to blocked arteries. It aims to see if the treatment is safe and may help improve heart function.
This trial tests a second dose of specialized immune cells (called CAR-DC) in patients with severe dilated cardiomyopathy (a weakened heart muscle) who received one dose before but saw their heart function decline back to baseline. The goal is to see if a second dose is safe and can improve heart function when the first treatment's benefits wore off.
This trial tests a new treatment called FAP iCDC for people with end-stage dilated cardiomyopathy, a type of heart muscle disease. It aims to see if this therapy is safe and helps improve heart function when standard medicines are no longer enough.
This trial tests a new treatment using heart muscle cells made from stem cells (iPSC-CMs) combined with either a heart pump (LVAD) or bypass surgery (CABG) for people with end-stage heart failure. The goal is to see if adding these cells can help the heart work better.
Hear when a new Cardiogenic Shock trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.